For years, marijuana policy in the United States has existed in an unusual gray area. More than half of the states allow marijuana for medical purposes, many also permit recreational use, and the legal cannabis industry has grown into a multibillion-dollar business. Yet under federal law, marijuana has remained a controlled substance, creating a persistent conflict between state and federal law.

That conflict may finally be starting to change. In April 2026, the U.S. Department of Justice and Drug Enforcement Administration took a significant step by moving FDA-approved marijuana products and marijuana products covered by qualifying state medical-marijuana licenses from Schedule I to Schedule III under the Controlled Substances Act. At the same time, the federal government began a new proceeding to determine whether marijuana more broadly should be moved from Schedule I to Schedule III.

The move is important, but it does not mean marijuana has been federally legalized. In fact, the United States is currently moving down two separate paths: one involves easing federal restrictions through rescheduling, while the other would require Congress to actually remove marijuana from the federal controlled-substance system.

Medical Marijuana Gets a Major Federal Change

The April decision represents one of the most substantial changes to federal marijuana policy in years.

Marijuana has historically been classified as a Schedule I substance, the most restrictive category under the Controlled Substances Act. Schedule I substances are considered to have a high potential for abuse and no currently accepted medical use under federal law.

The federal government has now created an important exception for medical marijuana.

FDA-approved marijuana products and marijuana products covered by qualifying state medical-marijuana licenses were placed into Schedule III. The Justice Department said the change was intended to expand access to approved therapies and support medical research while maintaining federal controls.

Schedule III is still a controlled-substance category, but it is considerably less restrictive than Schedule I. The change also has potential financial consequences for cannabis businesses because federal tax rules known as Section 280E have historically prevented businesses involved with Schedule I and Schedule II substances from deducting many ordinary business expenses.

That means rescheduling could improve the financial position of qualifying cannabis businesses even without making recreational marijuana federally legal.

The Bigger Question: What Happens to Recreational Marijuana?

This is where things get more complicated.

The April action specifically addressed FDA-approved marijuana products and marijuana covered by qualifying state medical-marijuana licenses. It did not federally legalize recreational cannabis.

The DEA subsequently held hearings beginning June 29, 2026, to consider the broader question of moving marijuana from Schedule I to Schedule III. Those hearings concluded in July.

A broader Schedule III classification would be a major change, but it still wouldn’t amount to full legalization.

A simple way to think about the possibilities is:

Schedule I: Marijuana remains in the most restrictive federal category.

Schedule III: The federal government recognizes accepted medical use and reduces some of the restrictions surrounding marijuana, but cannabis remains a controlled substance.

Descheduling: Marijuana is removed from the federal Controlled Substances Act’s scheduling system altogether.

Federal legalization: Congress establishes a legal federal framework allowing cannabis production, distribution and possession, subject to federal regulation.

The last two are much closer to what most people mean when they talk about “legalizing marijuana.”

The Rescheduling Process Just Hit a Roadblock

The broader Schedule III proceeding was moving toward a recommendation from the DEA’s administrative law judge. However, that process was unexpectedly paused in late September.

On September 29, Chief Administrative Law Judge Derek Julius stayed the proceeding while considering a request to add a new Government Accountability Office report to the record and allow additional briefing. The federal government has been given until October 13 to respond.

Importantly, this is a procedural delay, not a decision against rescheduling. The hearing itself had already concluded, and the stay does not change marijuana’s current federal classification.

The delay nevertheless matters because investors and the cannabis industry had been watching the proceeding for a decision on whether broader marijuana rescheduling would finally occur.

Could Marijuana Actually Be Legalized Nationwide?

Yes. There is currently legislation in Congress that would go considerably further than Schedule III.

In July 2026, Senator Cory Booker and other senators introduced the Cannabis Administration and Opportunity Act, known as S. 5022. The legislation would decriminalize and deschedule cannabis, create a federal regulatory framework, provide for the expungement of certain cannabis offenses and establish programs addressing communities affected by the War on Drugs.

That distinction is critical.

The DEA can potentially change marijuana’s scheduling through the federal administrative process. Congress, however, would be needed for a legislative solution that removes marijuana from federal scheduling altogether.

S. 5022 is therefore much closer to true federal legalization than the current Schedule III proceeding.

The bill was introduced on July 16 and referred to the Senate Finance Committee. It has not become law.

So while there is now an actual federal proposal for descheduling cannabis, its existence should not be confused with legalization being imminent.

Why the Difference Matters for the Cannabis Industry

The distinction between rescheduling and legalization could have enormous consequences for cannabis businesses.

Moving marijuana to Schedule III could provide immediate benefits to parts of the industry. Companies could potentially receive more favorable federal tax treatment, medical research could become easier, and the federal government’s recognition of marijuana’s medical applications would represent a significant departure from decades of policy.

But many of the industry’s biggest problems would remain.

Federal restrictions surrounding marijuana production, transportation, banking and interstate commerce would continue to create complications. A cannabis company operating legally in California, for example, would not automatically gain the ability to ship its products to customers in another state simply because marijuana had been moved to Schedule III.

Full descheduling would be a much larger event.

Removing marijuana from the federal controlled-substance schedules could fundamentally change how cannabis companies operate in the United States. It could open the door to broader financial services, more conventional business structures, interstate commerce and a national cannabis market, although Congress would still have to determine exactly how that market would be regulated.

So, Is Full Legalization Actually Coming?

It is too early to say that federal legalization is around the corner.

What is clear is that the federal government’s treatment of marijuana is changing. Medical marijuana has already received a significant federal classification change, and the broader question of Schedule III rescheduling is actively being considered. At the same time, members of Congress have introduced legislation that would go much further and remove cannabis from federal scheduling altogether.

The current situation could ultimately produce several different outcomes. Marijuana could remain federally controlled but move to Schedule III. Congress could eventually pass legislation descheduling cannabis. Or the country could continue with a patchwork system in which state legalization expands while federal law remains more restrictive.

For now, Schedule III is the immediate issue to watch, while full descheduling is the bigger prize for the cannabis industry.

If marijuana eventually moves from Schedule I to Schedule III, it would represent a major change in federal policy. If Congress goes further and removes marijuana from the Controlled Substances Act altogether, the impact could be considerably larger.

For investors, that distinction may be just as important as the question of whether marijuana becomes “legal.” Different stages of federal reform could benefit different parts of the cannabis industry, and companies that survive the current regulatory environment could find themselves operating in a dramatically different market if federal prohibition eventually comes to an end.